AI Article Synopsis
- Ventricular tachycardia (VT) in patients with structural heart disease has a higher risk of sudden cardiac death (SCD) and is primarily treated with implantable cardioverter-defibrillators (ICDs).
- In cases where antiarrhythmic drugs are not effective, catheter ablation can be used to treat or prevent repeated ICD shocks, improving patient outcomes.
- Some patients with frequent PVCs or VT might benefit from ablation before getting an ICD, as it can improve heart function and lower the SCD risk.
Article Abstract
In contrast to ventricular tachycardia (VT) that occurs in the setting of a structurally normal heart, VT that occurs in patients with structural heart disease carries an elevated risk for sudden cardiac death (SCD), and implantable cardioverter-defibrillators (ICDs) are the mainstay of therapy. In these individuals, catheter ablation may be used as adjunctive therapy to treat or prevent repetitive ICD therapies when antiarrhythmic drugs are ineffective or not desired. However, certain patients with frequent premature ventricular contractions (PVCs) or VT and tachycardiomyopathy should be considered for ablation before ICD implantation because left ventricular function may improve, consequently decreasing the risk of SCD and obviating the need for an ICD. The goal of this paper is to review the pathophysiology, mechanism, and management of VT in the setting of structural heart disease and discuss the evolving role of catheter ablation in decreasing ventricular arrhythmia recurrence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2017.10.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!